Cargando…
Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models
Adoptive chimeric antigen receptor-modified T or NK cells (CAR-T or CAR-NK) offer new options for cancer treatment. CAR-T therapy has achieved encouraging breakthroughs in the treatment of hematological malignancies. However, their therapeutic efficacy against solid tumors is limited. New regimens,...
Autores principales: | Zhang, Qing, Zhang, Haixu, Ding, Jiage, Liu, Hongyan, Li, Huizhong, Li, Hailong, Lu, Mengmeng, Miao, Yangna, Li, Liantao, Zheng, Junnian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6205314/ https://www.ncbi.nlm.nih.gov/pubmed/30410941 http://dx.doi.org/10.1155/2018/4263520 |
Ejemplares similares
-
Corrigendum to “Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models”
por: Zhang, Qing, et al.
Publicado: (2019) -
Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma
por: Zhang, Qing, et al.
Publicado: (2017) -
The detection of EpCAM(+) and EpCAM(–) circulating tumor cells
por: Wit, Sanne de, et al.
Publicado: (2015) -
Expression of EpCAM(MF) and EpCAM(MT) variants in human carcinomas
por: Fong, Dominic, et al.
Publicado: (2014) -
Targeted integration of EpCAM-specific CAR in human induced pluripotent stem cells and their differentiation into NK cells
por: Tang, Shin Yi, et al.
Publicado: (2021)